DiaMedica therapeutics (DMAC) shareholder TomEnterprise Private AB buys $10M in stock

DiaMedica Therapeutics (DMAC) has experienced significant positive momentum driven by a $9.99 million insider share purchase by TomEnterprise Private AB at $3.50 per share, increasing their stake to over 8.3 million shares. This follows a recently completed $30.1 million private placement to fund clinical development programs, notably for its DM199 asset. The company also reported positive interim Phase 2 results for DM199 in preeclampsia, leading H.C. Wainwright to raise its price target to $12.00, while the stock has rallied 20.8% in the past week. DMAC maintains a strong liquidity position and is set to report earnings on August 6, 2025.

Analysis

DiaMedica Therapeutics (DMAC) is exhibiting strong positive momentum driven by a confluence of catalysts. A significant insider transaction by 10% owner TomEnterprise Private AB, involving a nearly $10 million purchase of common stock at $3.50 per share, signals strong conviction from a key stakeholder. This event is complemented by the successful completion of a $30.1 million private placement, also priced at $3.50 per share, which bolsters the company's balance sheet and provides a clear funding runway for its clinical programs. The infusion of approximately $29.9 million in net proceeds is strategically timed, following positive interim results from the Phase 2 study of its lead asset, DM199, in preeclampsia, which met key safety and efficacy endpoints. This clinical success prompted an analyst upgrade from H.C. Wainwright, which raised its price target to $12.00. The company's financial position appears robust, with a current ratio of 8.02 and more cash than debt, mitigating near-term financing risks. Despite a recent 20.8% rally in the stock price to $5.05, it remains substantially below the analyst target range of $11 to $14.

Key Decisions for Investors

• The significant insider buying, coupled with a successful capital raise at the same price and positive clinical data, presents a strong bullish signal for initiating or increasing a position.
• Investors should closely monitor the upcoming earnings report on August 6, 2025, for further details on the clinical development timeline for DM199 and the updated cash burn rate.
• While the outlook is positive, recognize that as a clinical-stage biotech, DMAC's valuation is highly dependent on future trial outcomes, carrying inherent binary risk that should be factored into position sizing.